No a true issue. The main journal gets a bit more attention because it goes to wide array of unrelated doctors who want a general journal. This journal is targeted at exactly the correct audience AND it is false to presume it gets any less peer review than any other article presented by JAMA in any journal. It has lower distribution because it is not likely going to be in the office if heart doctors and baby doctors and unrelated doctors. It is going to get the attention of all executives at large pharma and likely all doctors and researchers doing ONCOLOGY. For them, it is no less than in fact JAMA, but a focused publication for their attention.
There are different ways to state this. One arguably say it has “less impact” because it does not go to all of those unrelated audiences. But that is a ridiculous statement and the impact can be seen by the congratulations messages and tweets from a variety of the most relevant and important target audience members.
So, yes, it’s not the general journal, with the largest distribution worldwide. It is JAMA, and that is not in doubt. It is not the general magazine that covers Alzheimer’s and Nutrition, heart disease and all manner of topics to be read by a general interest medical audience.
But honestly, for this particular research, I do not think the general publication would have been the best target for this disease and treatment at this time. It is very possible however that the next paper or a future paper may become general interest when there is more to report about DCVax as a general cancer vaccine.
News 
Market Data 
Discover 
AI
